Sign in to view content

Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients with nAMD Following a Modified Manufacturing Process

Raj K. Maturi, MD

Video
Published 2019

Related

Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration Across Key Clinical Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2018
Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of >4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Updates from the Field
2019
Ziv-aflibercept Efficacy in Better Regulating Neovascular AMD (ZEBRA) Trial
Kapil G. Kapoor, MD
On Demand Cases, Courses, and Papers
2019

Category: AMD-Neovascular

See more